Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN475 in patients with sciatic pain
NCT00991172Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2009
- Primary completion
- May 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fasinumab in Sciatica, sponsored by Regeneron Pharmaceuticals. Primary endpoint: Sciatic pain between baseline and end of week 4. Started Nov 2009; status: completed.
02
Drugs
fasinumab
03
Conditions
Sciatica
Beyond the preview
Go deeper on NCT00991172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00991172.